Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts.

British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
PEDIATRICS (Impact Factor: 5.3). 07/2006; 117(6):1963-71. DOI: 10.1542/peds.2005-2607
Source: PubMed

ABSTRACT We assessed adverse events, including oculorespiratory syndrome, following influenza immunization during the first year of a publicly-funded program for infants, toddlers and their household members in Canada.
Parents bringing infants and toddlers for influenza immunization to clinics in Quebec or British Columbia consented to structured telephone interview 5 to 10 days later. One adult provided information for all household members. Symptom experience commencing before and after immunization was assessed. Non-immunized persons also served as a comparison group for immunized household members.
Sample included 690 immunized infants and toddlers and 1801 household members, 1374 immunized. Only fussiness, fever, decreased appetite, drowsiness, and nasal congestion/coryza were reported for >5% of infants/ toddlers within 72 hours of immunization, but only arm discomfort was reported among >5% of immunized household contacts. In multivariate analysis, muscle ache was the only systemic symptom reported more often by immunized household members compared to non-immunized persons. Oculorespiratory symptoms were infrequent and there was no difference between immunized and non-immunized household members in their report. Less than 1% of adults required time off work because of adverse events following influenza immunization in the household. Less than 2% of subjects experiencing an adverse event following influenza immunization were considered unlikely to be vaccinated again.
Influenza vaccine is well-tolerated by infants, toddlers and their household members. Post-marketing observational designs are an expedient way to assess adverse events following influenza immunization. These methods should be established and rehearsed annually in preparation for a pandemic.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the improved efficacy of the nasal live-attenuated influenza virus vaccine (LAIV) compared with the injectable vaccine in children, we aimed to determine its safety in individuals with cystic fibrosis (CF).
    Pediatrics 09/2014; · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are limited summary data published on the risk of fever and febrile seizures in children following influenza vaccination. We performed a review of the risk of fever and febrile seizures following receipt of trivalent inactivated influenza vaccine (TIV) in children aged ≥6 months to <36 months, searching PubMED and Google Scholar for English language articles from 2000 onwards, and initiated or ongoing unpublished studies since September 2007 using Exclusions included other vaccine co-administration, missing ages or participant numbers, or unmeasured fever. We reviewed articles and collated results using a standard data extraction template. We identified a total of 909 published papers and unpublished trials from a search conducted on 23 January 2013, 669 from Google Scholar, 114 from PubMed and 126 from the online database. After excluding 890 published papers or unpublished trials, 5 published papers and 14 unpublished trials were included in this review. Extracted data on number of events, children at risk and time of follow-up were converted to the risk of fever, which was averaged per week of follow-up (referred to as 'averaged weekly risk'). Following one dose of TIV, the median averaged weekly risk of any fever (≥37.5°C) was 26.0% (range 10.3-70.0%) in unpublished trials compared to 8.2% (range 5.3-28.3%) in published papers (p=0.04). The median averaged weekly risk of severe fever (≥39.0°C) was 3.2% (range 0-10.0%) and 2.0% (range 0.6-17.0%), respectively (p=0.91). Variation in the reporting of fever by participant age groups, time since vaccination and the definition or measurement of fever resulted in a wide range of risk estimates. Reporting of febrile reactions should be standardised to allow comparison between manufacturers and influenza seasons.
    Vaccine 09/2013; · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunisation is an extremely safe public health intervention that provides huge health benefits by decreasing morbidity and mortality from infectious diseases. However, because of its success the general public do not experience any of these diseases first hand and so it becomes increasingly difficult to convey the importance of continued immunisation. More recently attention has also focussed on adverse events following immunisation – real or perceived. Post-immunisation surveillance plays a key role in detecting possible adverse events but interpretation of these temporal associations may be complex and can be misleading. This can be problematic when trying to achieve optimal vaccine uptake rates as it becomes difficult for parents to differentiate between fact and fiction. Knowledge of vaccines, their mechanism of action and their potential adverse effects is crucial in providing clear advice to parents. This review will explore some of the more high profile adverse events following immunisation, such as neurological disorders and autoimmune disorders and also focus on vaccine safety in premature infants.
    Paediatrics and Child Health 11/2008; 18(11):508-512. · 1.55 Impact Factor

Full-text (2 Sources)

Available from
Sep 22, 2014